Because of this, TP53 mutational screening for all patients before therapy start is recommended by the European Research Initiative on CLL group (ERIC) to avoid treatment protocols that are ineffective in patients with P53 dysfunction (79). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.